This is a preview of subscription content, log in via an institution to check access.
Rights and permissions
About this article
Cite this article
Tazobactam/piperacillin: continuous infusion cost-effective option. Pharmacoecon. Outcomes News 362, 5 (2002). https://doi.org/10.1007/BF03279042
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03279042